Pfizer Inc. $PFE Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 8,224,301 shares of the biopharmaceutical company’s stock after selling 456,998 shares during the quarter. New York State Common Retirement Fund’s holdings in Pfizer were worth $209,555,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Fiduciary Alliance LLC raised its holdings in shares of Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in Pfizer during the 3rd quarter worth approximately $3,019,000. Vista Investment Partners LLC raised its stake in Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares during the period. Generali Investments CEE investicni spolecnost a.s. lifted its holdings in shares of Pfizer by 76.4% in the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after purchasing an additional 47,319 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH boosted its position in shares of Pfizer by 11.2% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,892,663 shares of the biopharmaceutical company’s stock worth $48,225,000 after buying an additional 190,946 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on PFE (supportive near-term catalyst that helped shares earlier in the week). Why Is Pfizer Stock Rising Tuesday?
• Positive Sentiment: Some bullish analysts/investors remain confident in Pfizer’s longer-term outlook, arguing recent policy moves don’t change their favorable stance. Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
• Neutral Sentiment: Profile pieces and analyst roundups (CEO interview, market commentary) provide context but limited immediate price impact. Pfizer’s CEO on leading after a moonshot—and making deals with Trump
• Neutral Sentiment: Market write-ups note recent outperformance vs. the market on specific days, useful for sentiment tracking but not a structural change. Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
• Negative Sentiment: Zacks Research downgraded Pfizer from “hold” to “strong sell,” which can trigger selling pressure from momentum/quant strategies and affect sentiment. Zacks Downgrade Coverage
• Negative Sentiment: The U.S. Centers for Medicare & Medicaid Services named Pfizer drugs for the next round of Medicare price negotiations — a material policy risk that could pressure revenue for listed products if negotiated prices are reduced. US Medicare names drugs for next price talks
• Negative Sentiment: Earnings preview commentary warns Q4 results may decline versus expectations, raising the risk of a miss or muted guidance that could weigh on the stock. Earnings Preview: Q4 Earnings Expected to Decline
• Negative Sentiment: Competitive risk: early data from Aclaris shows a hair?loss candidate outperforming Pfizer’s Litfulo in preclinical/early results, a potential headwind for that franchise. Aclaris hair-loss drug shows faster results
• Negative Sentiment: Broader concerns about leverage and underperformance versus peers (Merck, J&J) keep analysts cautious ahead of secular headwinds like waning COVID product demand and an upcoming patent cliff. Pfizer vs. Merck Stock And JNJ

Pfizer Price Performance

Shares of PFE opened at $25.89 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market cap of $147.17 billion, a PE ratio of 15.05 and a beta of 0.47. The firm’s 50 day moving average price is $25.45 and its 200 day moving average price is $25.01. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on PFE shares. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Cantor Fitzgerald upped their target price on Pfizer from $24.00 to $27.00 and gave the company a “neutral” rating in a report on Tuesday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. HSBC reiterated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Finally, UBS Group started coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.